Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance

Stock Track

2025/10/31

Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.

Ardelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.

While the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1189182471"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189182471\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189182471?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 04:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189182471","market":"hk","top_or_hot":-1,"title":"Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.</p>\n\n<p>Ardelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.</p>\n\n<p>While the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 04:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.</p>\n\n<p>Ardelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.</p>\n\n<p>While the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1189182471","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189182471","pubTimestamp":1761856579,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"个股追踪|Ardelyx盘后大涨14.37%Q3业绩强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Shares of Ardelyx (NASDAQ: ARDX) jumped 14.37% in after-hours trading on Thursday following the release of the company's third-quarter 2025 financial results and corporate update. The biopharmaceutical company reported strong revenue growth and raised its full-year guidance for its lead product, IBSRELA.\nArdelyx reported total revenue of $110.3 million for the quarter, a 12.3% increase compared to the same period last year. The company's flagship product, IBSRELA, generated $78.2 million in revenue, representing a substantial 92% year-over-year growth. This impressive performance led Ardelyx to raise its full-year 2025 revenue guidance for IBSRELA to between $270 and $275 million.\nWhile the company reported a net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Ardelyx also announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}